Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial
2002 (English)In: American Journal of Hypertension, ISSN 0895-7061, Vol. 15, no 5, 389-93 p.Article in journal (Refereed) Published
BACKGROUND: Our aim was to determine whether the aldosterone synthase (CYP11B2) -344 C/T polymorphism was associated with the blood pressure (BP)-lowering response to antihypertensive treatment. METHODS: Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43). The aldosterone synthase (CYP11B2) -344 C/T polymorphism was analyzed using solid-phase minisequencing and related to BP reduction after 3 months treatment. Serum aldosterone levels were measured. RESULTS: After 3 months treatment the mean reductions in BP were similar for both treatment groups. When assessing the systolic BP reduction in the irbesartan group, patients with the TT variant had a more pronounced reduction (-21 +/- 19 SD mm Hg, n = 17) than both the TC (-14 +/- 18 mm Hg, n= 18) and CC (0 +/- 17 mm Hg, n = 8) genotypes (P = .04). There was no association between this polymorphism and the diastolic BP response. The -344 C/T polymorphism was not associated with the BP response to atenolol. Nor was it related to the baseline serum aldosterone level. CONCLUSIONS: The aldosterone synthase -344 C/T polymorphism was related to the BP-lowering response in hypertensive patients treated with the AT1-receptor antagonist irbesartan.
Place, publisher, year, edition, pages
2002. Vol. 15, no 5, 389-93 p.
Adrenergic beta-Antagonists/*therapeutic use, Aldosterone/blood, Aldosterone Synthase/*genetics, Antihypertensive Agents/*therapeutic use, Atenolol/*therapeutic use, Base Sequence/genetics, Biphenyl Compounds/*therapeutic use, Blood Pressure, Comparative Study, Cytosine, Double-Blind Method, Female, Humans, Hypertension/blood/*drug therapy/*genetics/physiopathology, Hypertrophy; Left Ventricular/drug therapy, Male, Middle Aged, Polymorphism; Genetic, Receptor; Angiotensin; Type 1, Receptors; Angiotensin/antagonists & inhibitors, Research Support; Non-U.S. Gov't, Tetrazoles/*therapeutic use, Thymine, Treatment Outcome
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-73165DOI: 10.1016/S0895-7061(02)02256-2PubMedID: 12022239OAI: oai:DiVA.org:uu-73165DiVA: diva2:101076